PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance.

Rose, Maddison; Burgess, Joshua T; O'Byrne, Kenneth; Richard, Derek J; Bolderson, Emma.

Afiliação

Rose M; Cancer & Ageing Research Program, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Translational Research Institute, Queensland University of Technology, Brisbane, QLD, Australia.
Burgess JT; Cancer & Ageing Research Program, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Translational Research Institute, Queensland University of Technology, Brisbane, QLD, Australia.
O'Byrne K; Cancer & Ageing Research Program, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Translational Research Institute, Queensland University of Technology, Brisbane, QLD, Australia.
Richard DJ; Princess Alexandra Hospital, Brisbane, QLD, Australia.
Bolderson E; Cancer & Ageing Research Program, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Translational Research Institute, Queensland University of Technology, Brisbane, QLD, Australia.

Front Cell Dev Biol ; 8: 564601, 2020.

Article em En | MEDLINE | ID: mdl-33015058